Mark Agulnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Agulnik has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Allen Lin Luo
Department of Medicine, Keck Medicine of USC, Los Angeles, CA, USA
1 shared publication Allen Seylani
Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
1 shared publication- Andrew John Cruz
Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA
1 shared publication Angela Hirbe
Division of Oncology, Washington University, St Louis, MO, USA
1 shared publicationAssal Sadighian
UC Riverside School of Medicine, Riverside, CA, USA
1 shared publicationBrian Schulte
Division of Oncology, University of California San Francisco, San Francisco, CA, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 139
Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Despite surgery and adjuvant imatinib for high-risk cases, recurrence remains high, often due to resistance from secondary kinase mutations. Imatinib is known to influence lipid metabolism in GIST and chronic myeloid leukemia (CML). This study evaluates metabolic trends in recurrent GIST post-resection to determine whether these biomarkers can signal resistance or early recurrence. Methods: This retrospective cohort study utilized de-identified data from the TriNetX database, comprising over 200 million patients across 172 healthcare systems in 18 countries. We examined total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), TG/HDL ratio, low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c, body mass index (BMI), and thyroid-stimulating hormone (TSH) in 36 patients with recurrent GIST on imatinib. Results: Thirty-six patients were included in this study. Patients underwent resection an average of 25.9 months before recurrence. Total cholesterol increased significantly (R=0.92, P=0.03), while LDL-C showed a similar increasing trend (R=0.87, P=0.050). HDL-C decreased significantly between pre- and post-recurrence periods (P=0.03). BMI differed between pre- and post-recurrence periods (P=0.047). TG showed a strong positive correlation (R=0.93, PConclusions: Patients with GIST recurrence demonstrated worsening metabolic profiles preceding recurrence—rising total cholesterol, LDL-C, TG, and BMI with declining HDL-C and TSH. Given imatinib’s usual lipid-lowering effects, reversal of this pattern may reflect emerging resistance. These metabolic biomarkers could serve as early, non-invasive indicators of recurrence and guide timely intervention.
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 139
Open AccessMetabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Despite surgery and adjuvant imatinib for high-risk cases, recurrence remains high, often due to resistance from secondary kinase mutations. Imatinib is known to influence lipid metabolism in GIST and chronic myeloid leukemia (CML). This study evaluates metabolic trends in recurrent GIST post-resection to determine whether these biomarkers can signal resistance or early recurrence. Methods: This retrospective cohort study utilized de-identified data from the TriNetX database, comprising over 200 million patients across 172 healthcare systems in 18 countries. We examined total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), TG/HDL ratio, low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c, body mass index (BMI), and thyroid-stimulating hormone (TSH) in 36 patients with recurrent GIST on imatinib. Results: Thirty-six patients were included in this study. Patients underwent resection an average of 25.9 months before recurrence. Total cholesterol increased significantly (R=0.92, P=0.03), while LDL-C showed a similar increasing trend (R=0.87, P=0.050). HDL-C decreased significantly between pre- and post-recurrence periods (P=0.03). BMI differed between pre- and post-recurrence periods (P=0.047). TG showed a strong positive correlation (R=0.93, PConclusions: Patients with GIST recurrence demonstrated worsening metabolic profiles preceding recurrence—rising total cholesterol, LDL-C, TG, and BMI with declining HDL-C and TSH. Given imatinib’s usual lipid-lowering effects, reversal of this pattern may reflect emerging resistance. These metabolic biomarkers could serve as early, non-invasive indicators of recurrence and guide timely intervention.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (4)
Liver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement
Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.
- 1 April 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (4)
Open AccessLiver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement
Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.
- 16 January 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (2) , 223-232
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
- 16 January 2026
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (2) , 223-232
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial